Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...
GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.
IMPAACT 2017 (MOCHA) week 96 results show long-acting Cabenuva (cabotegravir + rilpivirine) effectively maintained viral suppression in 94.4% of adolescents aged 12 to <18 years Additional paediatric ...
An FDA‑approved medication called spironolactone, often prescribed as a diuretic, or water pill, for heart and blood pressure conditions, may be a useful add‑on to the standard HIV treatment, ...
– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results